12,574
Total Claims
$3.5M
Drug Cost
1,182
Beneficiaries
$2,937
Cost/Patient
Peer Comparison vs. 6,382 Endocrinology providers
-25%
Cost per patient vs peers
$2,937 vs $3,933 avg
+10%
Brand preference vs peers
56.1% vs 51.2% avg
Brand vs Generic
44% generic
Brand: 6,650 claims · $3.3M
Generic: 5,200 claims · $100K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Insulin Lispro | 487 | $295K |
| Dulaglutide | 306 | $290K |
| Insulin Glargine,hum.Rec.Anlog | 645 | $278K |
| Empagliflozin | 272 | $231K |
| Dapaglifloz Propaned/Metformin | 333 | $228K |
| Insulin Glargine/Lixisenatide | 235 | $222K |
| Dapagliflozin Propanediol | 243 | $212K |
| Empaglifloz/Linaglip/Metformin | 327 | $209K |
| Levothyroxine Sodium | 1,682 | $172K |
| Empagliflozin/Metformin Hcl | 226 | $158K |
| Sitagliptin Phos/Metformin Hcl | 162 | $120K |
| Sitagliptin Phosphate | 138 | $110K |
| Insulin Nph Hum/Reg Insulin Hm | 243 | $110K |
| Insulin Glargine,hum.Rec.Anlog | 147 | $103K |
| Linagliptin | 113 | $81K |
Prescribing Profile
Patient Profile
70
Avg Age
69%
Female
2.08
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About